Abstract
Abdominal aortic aneurysm (AAA) is a common aortic disease with a progressive nature. There is no approved pharmacological treatment that would effectively slow the growth of the aneurysm or prevent rupture. Necrosis is a form of programmed necrosis that is regulated by receptor-interacting protein kinases (RIPs). We have recently shown that a lack of RIP3 in mice prevented aneurysm formation.
The aim of this study is to test whether disruptive necrosis affects the progression of existing aneurysms using RIP1 inhibitors Necrostatin-1 (Nec-1) and optimized forms of Nec-1, 7-Cl-O-Nec-1 (Nec-1 s). Seven days after induction of the aneurysm by elastase perfusion, mice were randomly administered DMSO, Nec-1 (3.2 mg / kg / day) and Nec-1s (1.6 mg / kg / day) by intraperitoneal injection. After sacrifice on day 14 of postaneurysm induction, the aortic expansion in the Nec-1s group (64.12 ± 4.80%) was significantly smaller than in the DMSO group (172.80 ± 13.68%) (P <0.05).
Product Details:
Alternate Name | 5-((7-Cl-1H-indol-3-yl)methyl)-3-methylimidazolidine-2,4-dione); 7-Cl-O-Nec-1 |
---|
Peptide Sequence | No |
---|
Appearance | Yellow solid |
---|
CAS # | 852391-15-2 |
---|
Molecular Formula | C₁₃H₁₂ClN₃O₂ |
---|
Molecular Weight | 277.71 |
---|
Purity | ≥96% by TLC and LC-MS |
---|
Solubility | DMSO |
---|
SMILES | CN1C(=O)C(NC1=O)CC2=CNC3=C2C=CC=C3Cl |
---|
InChi | InChI=1S/C13H12ClN3O2/c1-17-12(18)10(16-13(17)19)5-7-6-15-11-8(7)3-2-4-9(11)14/h2-4,6,10,15H,5H2,1H3,(H,16,19) |
---|
InChi Key | WIKGAEMMNQTUGL-UHFFFAOYSA-N |
---|
PubChem CID | 643953 |
---|
Handling | Protect from light and moisture |
---|
Storage Conditions | -20°C |
---|
Shipping Conditions | Gel Pack |
---|
USAGE | For Research Use Only! Not For Use in Humans. |
---|
biovision nec 1s
Descriptions:
A potent necroptosis inhibitor. Displays higher activity in inhibiting necroptosis in Jurkat cells than Nec-1 (Cat. No. 1864) (EC₅₀ = 210 nM versus EC₅₀ = 490 nM), as well as showing no nonspecific cytotoxicity at high concentrations (~100 mM). More useful for in-cell and in vivo experiments compared to Nec-1.
The mean aortic diameter of Nec-1-treated mice appeared to be smaller (121.60 ± 10.40%) than the DMSO group, although the difference was not statistically significant (P = 0.1). Histologically, the aortic structure of Nec-1s-treated mice appeared normal, with continuous and organized elastin layers and rich SMCs expressing αActin. In addition, Nect-1 treatment reduced macrophage infiltration and MMP9 accumulation and increased tropoelastin and lysyl oxidase aortic levels. Together, our data suggest that pharmacological inhibition of necrosis by Nec-1 stabilizes pre-existing aneurysms by reducing inflammation and promoting connective tissue repair.
NOMO-1s |
ABL-TC0480 | AcceGen | 1 vial | Ask for price |
Description: NOMO-1s Cell Line is from human; Tissue: hemo-lymphocytic; Morphology: round; Profile: This cell line is useful for studying the differentiation and maturation of monocytes. |
(1S)-Chrysanthemolactone |
TN2671-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
(1S)-Chrysanthemolactone |
TN2671-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
(1S)-Chrysanthemolactone |
TN2671-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
(1S)-Chrysanthemolactone |
TN2671-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
(1S)-Chrysanthemolactone |
TN2671-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: (1S)-Chrysanthemolactone |
MM.1S |
CSC-C9219W | Creative Bioarray | One Frozen vial | Ask for price |
Description: Leukemia - Lymphoma - Myeloma Cells |
IQ-1S |
abx282388-100g | Abbexa | 100 µg | Ask for price |
IQ-1S |
abx282388-20g | Abbexa | 20 µg | EUR 118.75 |
IQ-1S |
abx282388-50g | Abbexa | 50 µg | EUR 225 |
Growth Medium 1S |
78221 | BPS Bioscience | 500 ml | EUR 650 |
Description: This liquid Growth Medium is a complete medium optimized to culture select BPS Bioscience cell lines.Optimized for Use With: CRISPRa (SAM) HeLa Cell Line (BPS Bioscience, #78193), CRISPRa (SAM) HepG2 Cell Line (BPS Bioscience, #78194) |
(1S,3R)-ACPD |
B6245-10 | ApexBio | 10 mg | EUR 350 |
|
Description: group I and II mGlu receptor agonist |
(1S,3R)-ACPD |
B6245-50 | ApexBio | 50 mg | EUR 1441 |
|
Description: group I and II mGlu receptor agonist |
(1S)-(-)-α-Pinene |
C7097-100 | ApexBio | 100mg | EUR 32 |
|
(1S)-(-)-α-Pinene |
C7097-200 | ApexBio | 200mg | EUR 40 |
|
(1S,2S)-Bortezomib |
T10061-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: (1S,2S)-Bortezomib |
(1S,2S)-Bortezomib |
T10061-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: (1S,2S)-Bortezomib |
(1S,2S)-Bortezomib |
T10061-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: (1S,2S)-Bortezomib |
(1S,2S)-Bortezomib |
T10061-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: (1S,2S)-Bortezomib |
(1S,2S)-Bortezomib |
T10061-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: (1S,2S)-Bortezomib |